• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BioLineRx Ltd.

    1/23/26 4:15:08 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLRX alert in real time by email
    S-8 1 zk2634171.htm S-8
    As filed with the Securities and Exchange Commission on January 23, 2026.
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    __________________________

    FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    __________________________

    BIOLINERX LTD.
    (Exact Name of Registrant as Specified in its Charter)
    __________________________

    State of Israel
    Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer Identification No.)
    __________________________

    BioLineRx Ltd.
    2 HaMa’ayan Street
    Modi’in 7177871, Israel
    (972) (8) 642-9100
    (Address of principal executive offices)
    __________________________

    BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan
    (Full title of the Plan)
    __________________________

    BioLineRx USA, Inc.
    77 Fourth Ave
    Waltham, Massachusetts 02451
    (617) 859-6409
    (Name, Address, including zip code, and telephone number, including area code, of agent for service)
    __________________________

    Copies of all correspondence to:

    Gary Emmanuel, Esq.
    Greenberg Traurig, P.A.
    One Azrieli Center
    Round Tower, 30th floor
    132 Menachem Begin Rd
    Tel Aviv 6701101
    Tel: +972 (0) 3.636.6000
    Sharon Rosen, Adv.
    FISCHER (FBC & Co.)
    146 Menachem Begin Street
    Tel Aviv 6492103, Israel
    Tel: +972 -3-6944111
    __________________________

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☐
     
     
    Emerging growth company
    ☐




    EXPLANATORY NOTE

    BioLineRx, Ltd. (the “Company”) initially filed a registration statement on Form S-8 (SEC File No. 333-176419) with the Securities and Exchange Commission (the “SEC”) in connection with the registration of an aggregate of 1,000,000 Ordinary Shares (equivalent to 1,666 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan, or the Plan. In September 2012, the Company filed another registration statement on Form S-8 (SEC File No. 333-183976) in connection with the registration of an additional 2,000,000 Ordinary Shares (equivalent to 3,333 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the Plan. In December 2014, the Company filed another registration statement on Form S-8 (SEC File No. 333-201326) in connection with the registration of an additional 1,600,000 Ordinary Shares (equivalent to 2,666 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the Plan. In January 2016, the Company filed another registration statement on Form S-8 (SEC File No. 333-208865) in connection with the registration of an additional 5,000,000 Ordinary Shares (equivalent to 8,333 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the Plan, as amended by Post-Effective Amendment No. 1 on Form S-8 filed in March 2017. In January 2023, the Company filed another registration statement on Form S-8 (SEC File No. 333-269334) in connection with the registration of an additional 106,218,486 Ordinary Shares (equivalent to 177,030 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the Plan. In December 2023, the Company filed another registration statement on Form S-8 (SEC File No. 333-276325) in connection with the registration of an additional 57,500,000 Ordinary Shares (equivalent to 95,833 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the Plan. In December 2024, the Company filed another registration statement on Form S-8 (SEC File No. 333-284059) in connection with the registration of an additional 30,000,000 Ordinary Shares (equivalent to 50,000 ADSs, based on each ADS representing 600 ordinary shares) to be issued under the Plan. These previously-filed registration statements are referred to collectively herein as the “Prior Registration Statements.”

    In accordance with General Instruction E to Form S-8, the Company is filing this registration statement on Form S-8 solely to register an additional 360,000,000 Ordinary Shares (equivalent to 600,000 ADSs, with each ADS representing 600 ordinary shares) which may be issued under the Plan over and above the number of Ordinary Shares issuable pursuant to the Plan that were registered under the Prior Registration Statements. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference in their entirety, with the exception of Items 3 and 8 of Part II of such Prior Registration Statements, each of which is amended and restated in its entirety herein.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The SEC allows the Company to incorporate by reference our publicly filed reports into this prospectus, which means that information included in those reports is considered part of this prospectus. Information that we file with the SEC after the date of this prospectus will automatically update and supersede the information contained in this prospectus. We incorporate by reference the following documents filed with the SEC and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended:

     
    •
    our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 31, 2025;
     
     
     
     
    •
    our Reports on Form 6-K filed with the SEC on March 31, 2025, May 23, 2025, May 27, 2025, May 30, 2025, June 30, 2025, August 14, 2025, September 29, 2025, November 17, 2025 and November 24, 2025 (in each case, to the extent expressly incorporated by reference into our effective registration statements filed by us under the Securities Act); and
     
     
     
     
    •
    the description of our ordinary shares contained in Exhibit 2.2 to our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 31, 2025, including any amendment or report filed with the SEC for the purpose of updating such description.

    All documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the filing of a post-effective amendment that indicates that all securities have been offered and sold or that deregisters all securities remaining unsold shall be deemed to be incorporated by reference in the registration statement and to be a part hereof from the date of filing of such documents (other than information that is furnished in such documents but deemed by the rules of the SEC not to have been filed). Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.



    We will furnish without charge to you, on written or oral request, a copy of any or all of the above documents, other than exhibits to such documents which are not specifically incorporated by reference therein. You should direct any requests for documents to:

     
    BioLineRx Ltd.
    2 HaMa’ayan Street
    Modi’in 7177871, Israel
    Attention: Corporate Secretary
    Tel.: +972-8-642-9100
    e-mail: [email protected]

    Item 8. Exhibits.

    Exhibit
    Number
     
    Exhibit Description
     
    Method of Filing
     

     
     
     
    4.1

    BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan
     
    Filed herewith.
     

     
     
     
    5.1

    Opinion of FISCHER (FBC & Co), as to the legality of the securities being registered
     
    Filed herewith.
     

     
     
     
    23.1

    Consent of FISCHER (FBC & Co) included in Exhibit 5.1)
     
    Filed herewith.
     

     
     
     
    23.2

    Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant
     
    Filed herewith.
     

     
     
     
    24.1

    Power of Attorney (included on signature page)
     
    Filed herewith.
     

     
     
     
    107

    Filing Fee Table
     
    Filed herewith.



    Item 9. Undertakings.

    The undersigned registrant hereby undertakes:

    (1)          to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement;
     
    (i)          to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)          to reflect in the prospectus any facts or events arising after the effective date of the Registration statement (or most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the change in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

    (iii)          to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement;

    (2)          that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)          to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Modi’in, State of Israel, on January 23, 2026.
    .
     
    BIOLINERX LTD.
     
     
     
     
     
     
    By:
    /s/ Philip A. Serlin
     
     
     
    Philip A. Serlin
     
     
     
    Chief Executive Officer
     

    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENTS, that each director and officer of BIOLINERX LTD. whose signature appears below hereby constitutes and appoints Philip A. Serlin and Mali Ze’evi, and each of them severally, acting alone and without the other, his/her true and lawful attorney-in-fact with full power of substitution or re-substitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign on such person’s behalf, individually and in each capacity stated below, any and all amendments, including post-effective amendments to this Registration Statement, and to sign any and all additional registration statements relating to the same offering of securities of the Registration Statement that are filed pursuant to Rule 462(b) of the Securities Act of 1933 and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated:

    SIGNATURE
     
    TITLE
     
    DATE
     
     
     
     
     
    /s/ Philip A. Serlin
     
    Chief Executive Officer,
     
    January 23, 2026
    Philip A. Serlin
     
    (Principal Executive Officer)
     
     
     
     
     
     
     
    /s/ Mali Zeevi
     
    Chief Financial Officer
     
    January 23, 2026
    Mali Zeevi
     
    (Principal Financial and Accounting Officer)
     
     
     
     
     
     
     
    /s/ Aharon Schwartz
     
    Chairman of the Board
     
    January 23, 2026
    Aharon Schwartz
     
     
     
     
     
     
     
     
     
    /s/ B.J. Bormann
     
    Director
     
    January 23, 2026
    B.J. Bormann
     
     
     
     
     
     
     
     
     
    /s/ Gal Cohen
     
    Director
     
    January 23, 2026
    Gal Cohen
     
     
     
     
     
     
     
     
     
    /s/ Rami Dar
     
    Director
     
    January 23, 2026
    Rami Dar
     
     
     
     
     
     
     
     
     
    /s/ Raphael Hofstein
     
    Director
     
    January 23, 2026
    Raphael Hofstein
     
     
     
     
     
     
     
     
     
    /s/ Avraham Molcho
     
    Director
     
    January 23, 2026
    Avraham Molcho
     
     
     
     
     
     
     
     
     
    /s/ Sandra Panem
     
    Director
     
    January 23, 2026
    Sandra Panem
     
     
     
     
     
     
     
     
     
    /s/ Shaoyu Yan
     
    Director
     
    January 23, 2026
    Shaoyu Yan
     
     
     
     



    AUTHORIZED REPRESENTATIVE
     
    Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of BioLineRx Ltd. has signed this registration statement on January 23, 2026.
     
     
    BioLineRx USA, Inc.
     
     
     
     
     
     
    By: 
    /s/ Philip A. Serlin
     
     
     
    Name: Philip A. Serlin
     
     
     
    Title: Authorized Person
     


    Get the next $BLRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for APHEXDA issued to BIOLINERX, LTD.

    Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

    9/11/23 2:15:50 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    SEC Filings

    View All

    SEC Form S-8 filed by BioLineRx Ltd.

    S-8 - BioLineRx Ltd. (0001498403) (Filer)

    1/23/26 4:15:08 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BioLineRx Ltd.

    6-K - BioLineRx Ltd. (0001498403) (Filer)

    11/24/25 7:00:17 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BioLineRx Ltd.

    6-K - BioLineRx Ltd. (0001498403) (Filer)

    11/17/25 7:12:44 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright reiterated coverage on BioLineRx with a new price target

    HC Wainwright reiterated coverage of BioLineRx with a rating of Buy and set a new price target of $19.00 from $22.00 previously

    3/1/21 8:36:34 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright resumed coverage on BioLineRx

    HC Wainwright resumed coverage of BioLineRx with a rating of Buy

    2/23/21 11:53:43 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on BioLine Rx with a new price target

    HC Wainwright & Co. reiterated coverage of BioLine Rx with a rating of Buy and set a new price target of $19.00 from $22.00 previously

    2/23/21 11:24:05 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24th, at 8:30 am EST - TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update. "The clear highlight of the third quarter was our announc

    11/24/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors

    Patent protects the use of GLIX1 in cancers where cytidine deaminase (CDA) is not over-expressed — representing more than 90% of all cancer types Hemispherian AS, a biotechnology company pioneering first-in-class TET2-activating therapeutics for difficult-to-treat cancers, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application titled "Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies" (U.S. Patent Application No. 18/602,969). The patent covers the use of Hemispherian's lead clinical candidate, GLIX1, for the treatment of cancers in which cytidine deaminase (CDA) is not over-expressed beyond a defined

    11/19/25 3:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

    Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2025 on Monday, November 24, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can

    11/18/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Leadership Updates

    Live Leadership Updates

    View All

    Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

    Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

    2/18/25 8:00:00 AM ET
    $ALLT
    $BLRX
    $CGEN
    Computer Communications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

    Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

    12/10/24 8:30:00 AM ET
    $BLRX
    $SLXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

    Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.  Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions.  Her appointment is effective today, January 4, 2023. "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx. 

    1/4/23 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Financials

    Live finance-specific insights

    View All

    BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24th, at 8:30 am EST - TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update. "The clear highlight of the third quarter was our announc

    11/24/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

    Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel, Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2025 on Monday, November 24, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can

    11/18/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

    - GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - - BioLineRx affirms its cash runway into the first half of 2027 - - Management to host conference call today, September 29th, at 8:30 am EDT - TEL AVIV, Israel and OSLO, Norway, Sept. 29, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS,

    9/29/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by BioLineRx Ltd. (Amendment)

    SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

    2/11/22 6:49:45 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

    2/16/21 4:10:22 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

    2/12/21 9:40:57 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care